• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Precision Therapy of Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌的精准治疗。
J Dent Res. 2018 Jun;97(6):614-621. doi: 10.1177/0022034518769645. Epub 2018 Apr 12.
2
Leveraging Genomics for Head and Neck Cancer Treatment.利用基因组学进行头颈部癌症治疗。
J Dent Res. 2018 Jun;97(6):603-613. doi: 10.1177/0022034518756352. Epub 2018 Feb 8.
3
Genomics and precision surgery for head and neck squamous cell carcinoma.头颈部鳞状细胞癌的基因组学与精准外科
Cancer Lett. 2020 Jul 1;481:45-54. doi: 10.1016/j.canlet.2020.04.004. Epub 2020 Apr 6.
4
Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.迈向精准医学在头颈部鳞状细胞癌治疗中的应用。
Oncotarget. 2017 Jan 10;8(2):2141-2152. doi: 10.18632/oncotarget.13798.
5
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.头颈部癌症中微环境驱动的肿瘤内异质性:精准医学的临床挑战和机遇。
Drug Resist Updat. 2022 Jan;60:100806. doi: 10.1016/j.drup.2022.100806. Epub 2022 Jan 25.
6
Nucleic acid targeting: towards personalized therapy for head and neck cancer.核酸靶向:迈向头颈癌个性化治疗
Oncogene. 2016 Jun 23;35(25):3217-26. doi: 10.1038/onc.2015.424. Epub 2015 Nov 23.
7
Molecular Aspects of Head and Neck Cancer Therapy.头颈癌治疗的分子层面
Hematol Oncol Clin North Am. 2015 Dec;29(6):971-92. doi: 10.1016/j.hoc.2015.07.003. Epub 2015 Oct 17.
8
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.头颈部鳞状细胞癌的研究进展:2015年国际头颈部肿瘤研究学会(ICHTO)最佳摘要
Am Soc Clin Oncol Educ Book. 2015:e323-8. doi: 10.14694/EdBook_AM.2015.35.e323.
9
Head and Neck Cancer in the New Era of Precision Medicine.精准医学新时代的头颈癌
J Dent Res. 2018 Jun;97(6):601-602. doi: 10.1177/0022034518772278.
10
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.头颈部癌症中的精准医学和下一代测序的当前趋势。
Curr Treat Options Oncol. 2022 Feb;23(2):254-267. doi: 10.1007/s11864-022-00942-8. Epub 2022 Feb 23.

引用本文的文献

1
Identification of a novel necroptosis-related LncRNA signature for prognostic prediction and immune response in oral squamous cell carcinoma.鉴定口腔鳞状细胞癌中新型坏死性相关 LncRNA 特征用于预后预测和免疫反应
Cancer Biomark. 2024;40(3-4):319-342. doi: 10.3233/CBM-230407.
2
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC).免疫调节在治疗头颈部鳞状细胞癌(HNSCC)中的应用
Cells. 2024 Feb 27;13(5):413. doi: 10.3390/cells13050413.
3
Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature.头颈部鳞状细胞癌肿瘤免疫微环境的研究进展:文献综述
Medicine (Baltimore). 2024 Mar 1;103(9):e37387. doi: 10.1097/MD.0000000000037387.
4
AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.AIM2 通过激活 STAT1/NF-κB 促进口腔鳞状细胞癌的辐射抗性、迁移能力和 PD-L1 表达。
J Transl Med. 2024 Jan 3;22(1):13. doi: 10.1186/s12967-023-04825-w.
5
Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment.头颈部癌联合分子靶向治疗的优势——基于适应性个性化治疗的前一步。
Cancers (Basel). 2023 Aug 24;15(17):4247. doi: 10.3390/cancers15174247.
6
miR-30e-5p-mediated FOXD1 promotes cell proliferation by blocking cellular senescence and apoptosis through p21/CDK2/Rb signaling in head and neck carcinoma.miR-30e-5p介导的FOXD1通过p21/CDK2/Rb信号通路阻断细胞衰老和凋亡,从而促进头颈癌的细胞增殖。
Cell Death Discov. 2023 Aug 10;9(1):295. doi: 10.1038/s41420-023-01571-2.
7
Diagnostic, Prognostic, and Therapeutic Role for Angiogenesis Markers in Head and Neck Squamous Cell Carcinoma: A Narrative Review.血管生成标志物在头颈部鳞状细胞癌中的诊断、预后和治疗作用:叙述性综述。
Int J Mol Sci. 2023 Jun 27;24(13):10733. doi: 10.3390/ijms241310733.
8
Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity.口腔鳞状细胞癌与口腔癌前病变中 PD-L1 表达的比较。
Asian Pac J Cancer Prev. 2022 Dec 1;23(12):4039-4045. doi: 10.31557/APJCP.2022.23.12.4039.
9
Relationships of Ferroptosis and Pyroptosis-Related Genes with Clinical Prognosis and Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中与铁死亡和焦亡相关基因与临床预后及肿瘤免疫微环境的关系。
Oxid Med Cell Longev. 2022 Oct 5;2022:3713929. doi: 10.1155/2022/3713929. eCollection 2022.
10
Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌中 MYC 的治疗靶点。
Oncoimmunology. 2022 Sep 30;11(1):2130583. doi: 10.1080/2162402X.2022.2130583. eCollection 2022.

本文引用的文献

1
Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.工程疫苗以重新编程对头颈部癌症的免疫反应。
J Dent Res. 2018 Jun;97(6):627-634. doi: 10.1177/0022034518764416. Epub 2018 Mar 13.
2
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.宿主细胞上的 PD-L1 对于 PD-L1 阻断介导的肿瘤消退是必需的。
J Clin Invest. 2018 Feb 1;128(2):580-588. doi: 10.1172/JCI96061. Epub 2018 Jan 16.
3
Genomics and advances towards precision medicine for head and neck squamous cell carcinoma.头颈鳞状细胞癌的基因组学与精准医学进展
Laryngoscope Investig Otolaryngol. 2017 Aug 22;2(5):310-319. doi: 10.1002/lio2.86. eCollection 2017 Oct.
4
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.美国食品药品监督管理局首次批准与癌症部位无关——当生物标志物确定适应症时。
N Engl J Med. 2017 Oct 12;377(15):1409-1412. doi: 10.1056/NEJMp1709968.
5
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.纳武单抗和派姆单抗:可互换的抗程序性细胞死亡蛋白1(PD-1)单克隆抗体。
Semin Oncol. 2017 Apr;44(2):132-135. doi: 10.1053/j.seminoncol.2017.06.007. Epub 2017 Jul 13.
6
PD-1 Status in CD8 T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.CD8⁺ T细胞中的PD-1状态与头颈癌的生存率及抗PD-1治疗结果相关。
Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.
7
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.帕博利珠单抗治疗程序性死亡配体 1 阳性鼻咽癌患者的安全性和抗肿瘤活性:KEYNOTE-028 研究结果。
J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.
8
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.个体化 RNA 突变疫苗可动员针对癌症的多特异性治疗性免疫。
Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.
9
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.纳武利尤单抗对比研究者选择的标准单药疗法用于复发性或转移性头颈部鳞状细胞癌(CheckMate 141):一项随机3期试验的健康相关生活质量结果
Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.
10
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.头颈部鳞状细胞癌(SCCHN)中全身用药的毒性;免疫治疗时代的新视角。
Crit Rev Oncol Hematol. 2017 Jul;115:50-58. doi: 10.1016/j.critrevonc.2017.04.011. Epub 2017 Apr 27.

头颈部鳞状细胞癌的精准治疗。

Precision Therapy of Head and Neck Squamous Cell Carcinoma.

机构信息

1 Department of Periodontics and Oral Medicine, Division of Oral Medicine, Pathology, and Radiology, University of Michigan School of Dentistry, Ann Arbor, MI, USA.

2 Department of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.

出版信息

J Dent Res. 2018 Jun;97(6):614-621. doi: 10.1177/0022034518769645. Epub 2018 Apr 12.

DOI:10.1177/0022034518769645
PMID:29649374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5960884/
Abstract

Precision medicine is an approach to disease prevention and treatment that takes into account genetic variability and environmental and lifestyle influences that are unique to each patient. It facilitates stratification of patient populations that vary in their susceptibility to disease and response to therapy. Shared databases and the implementation of new technology systems designed to advance the integration of this information will enable health care providers to more accurately predict and customize prevention and treatment strategies for patients. Although precision medicine has had a limited impact in most areas of medicine, it has been shown to be an increasingly successful approach to cancer therapy. Despite early promising results targeting aberrant signaling pathways or inhibitors designed to block tumor-driven processes such as angiogenesis, limited success emphasizes the need to discover new biomarkers and treatment targets that are more reliable in predicting response to therapy and result in better health outcomes. Recent successes in the use of immunity-inducing antibodies have stimulated increased interest in the use of precision immunotherapy of head and neck squamous cell carcinoma. Using next-generation sequencing, the precise profiling of tumor-infiltrating lymphocytes has great promise to identify hypoimmunogenic cancer that would benefit from a rationally designed combinatorial approach. Continued interrogation of tumors will reveal new actionable targets with increasing therapeutic efficacy and fulfill the promise of precision therapy of head and neck cancer.

摘要

精准医学是一种疾病预防和治疗的方法,它考虑到了每个患者特有的遗传变异性以及环境和生活方式的影响。它有助于对疾病易感性和治疗反应不同的患者人群进行分层。共享数据库和实施旨在推进信息整合的新技术系统,将使医疗保健提供者能够更准确地预测和定制患者的预防和治疗策略。尽管精准医学在大多数医学领域的影响有限,但它已被证明是癌症治疗中越来越成功的方法。尽管针对异常信号通路或旨在阻断血管生成等肿瘤驱动过程的抑制剂的早期有希望的结果,但有限的成功强调需要发现更可靠的新生物标志物和治疗靶点,以更好地预测治疗反应并改善健康结果。最近使用免疫诱导抗体的成功激发了对头颈部鳞状细胞癌精准免疫治疗的兴趣增加。使用下一代测序,对肿瘤浸润淋巴细胞的精确分析有望识别出受益于合理设计的组合方法的低免疫原性癌症。对肿瘤的持续研究将揭示具有更高治疗效果的新治疗靶点,并实现头颈部癌症精准治疗的承诺。